⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

July 2, 2026Journal of Medicinal ChemistryOpen Access

A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity

Jianping Lin Brenson A. Jassim Yunpeng Bai Zihan Qu Frederick Nguele Meke Jiajun Dong W Li Benjamin Ayodipupo Babalola Jingmei Yu Haoran Zhang Z Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to investigate a quinolone-based PTPN22 inhibitor's capacity to enhance antitumor immunity.
Utilized a quinolone derivative as an inhibitor of PTPN22.
Evaluated immunotherapeutic activity through in vitro assays and animal models.
Assessed antitumor effects based on immune response metrics.
The inhibitor significantly increased antitumor immune responses.
Enhanced activity was associated with improved tumor reduction compared to controls.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Reveals improved immunotherapeutic activity of a quinolone-based PTPN22 inhibitor, suggesting potential for novel anticancer agents.

Abstract

by promoting robust antitumor immunity, thus offering a promising lead molecule for the development of novel anticancer agents targeting PTPN22.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a48a4c689561a0c2d78dde3 https://doi.org/10.1021/acs.jmedchem.5c03467

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunityClinical Trial · 2023 · 101 citations
2Discovery of HDM2010, a highly potent PTPN2 inhibitor for immunotherapy.2024 · 1 citations
3Abstract 7926: Efficacy, <i>in vivo</i> safety, and PK/PD studies for novel, oral, highly selective PTPN2/1 inhibitor (ZE00-0388)Original Research · 2026
4Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy2024
5Advances in Quinazolinone‐Based Tumor‐Targeted InhibitorsReview · 2026
6Little ones can do big things: Small molecule inhibitors target PTPN2/PTPN1 for tumor immunotherapy2024 · 1 citations
7Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy2024 · 2 citations
8Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights2025 · 2 citations
9Combinatorial Synthesis and Direct-to-Biology Antibacterial Evaluation of Ruthenium(II) and Iridium(III) N^O -Schiff−Base ComplexesJournal of Medicinal Chemistry · 2026
10Design, Synthesis, and Evaluation of 99mTc-Labeled PSMA-Targeting Dimeric Tracers: Comparison of Glutamate−Urea−Lysine (EuK) and Aminoadipic Acid−Urea−Lysine (AuK) Targeting GroupsJournal of Medicinal Chemistry · 2026

More from Journal of Medicinal Chemistry

More from Purdue University West Lafayette

More from Tarpo (Czechia)